Form 4 for NVCR NovoCure Ltd
Accepted 2023-06-09 00:00:00 ET · period of report 2023-06-07 · accession 0001562180-23-005013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-09 | 2023-06-07 | NVCR | LEUNG GABRIEL | Dir | A - Grant | $0.00 | +3,853 | 79.1K | +5% | $0 |
| D | 2023-06-09 | 2023-06-07 | NVCR | LEUNG GABRIEL | Dir | A - Grant | $0.00 | +6,277 | 6,277 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Restricted Stock Units | 2023-06-07 | A | A | 3,853 | $0.00 | 79,139 | D | — | — | (F1) These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-06-07 | A | A | 6,277 | $0.00 | 6,277 | D | $48.66 · 2024-06-07 to 2033-06-06 | 6,277 Ordinary Shares | (F2) Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. |